Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen.
Eur J Gynaecol Oncol
; 37(5): 700-702, 2016.
Article
en En
| MEDLINE
| ID: mdl-29787014
ABSTRACT
OBJECTIVE:
To evaluate polymorphism frequency of the CYP2D6*4, *10, and * 17 alleles in women with breast cancer treated with tamoxifen. MATERIALS ANDMETHODS:
Ninety-five women with estrogen and progesterone receptor-positive breast carcinoma were investigated from September to December 2013. A three-ml sample of peripheral blood was collected from each patient to analyze the presence of CYP2D6 *4, *10, and *17 allele polymorphism by specific polymerase chain reaction technique (PCR) for analysis of haplotypes *1, *4, *10, and *17, determined by studies of different single-nucleotide polymorphism (SNP). The data obtained were compiled and analyzed with the aid of Excel software 2010.RESULTS:
The frequency of CYP2D6 alleles *4, *10, and *17 was 16%, 29%, and 2%, respectively, and haplotype * 1/*10 was shown in 22% of the women. The phenotype of intermediate metabolism occurred in 8% of women.CONCLUSIONS:
The present study showed a deficiency in tamoxifen metabolism, characterized by intermediate metabolism in 8% of Brazilian women.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Tamoxifeno
/
Neoplasias de la Mama
/
Antineoplásicos Hormonales
/
Citocromo P-450 CYP2D6
/
Polimorfismo de Nucleótido Simple
Límite:
Female
/
Humans
Idioma:
En
Año:
2016
Tipo del documento:
Article